ES2164916T3 - Tratamiento de la esclerosis multiple. - Google Patents

Tratamiento de la esclerosis multiple.

Info

Publication number
ES2164916T3
ES2164916T3 ES96929924T ES96929924T ES2164916T3 ES 2164916 T3 ES2164916 T3 ES 2164916T3 ES 96929924 T ES96929924 T ES 96929924T ES 96929924 T ES96929924 T ES 96929924T ES 2164916 T3 ES2164916 T3 ES 2164916T3
Authority
ES
Spain
Prior art keywords
multiple sclerosis
treatment
symptoms
patient
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96929924T
Other languages
English (en)
Inventor
Hector F Deluca
Colleen E Hayes
Margherita T Cantorna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Application granted granted Critical
Publication of ES2164916T3 publication Critical patent/ES2164916T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transplanting Machines (AREA)
  • Control Of Vehicles With Linear Motors And Vehicles That Are Magnetically Levitated (AREA)
  • Exposure Control For Cameras (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE DESCRIBE UN METODO DE TRATAMIENTO DE LOS SINTOMAS DE LA ESCLEROSIS MULTIPLE DE UN PACIENTE CON ESCLEROSIS MULTIPLE, CONSISTENTE EN LA ADMINISTRACION A DICHO PACIENTE DE UNA CANTIDAD DE UN COMPUESTO DE VITAMINA D QUE SEA EFECTIVA PARA REDUCIR LOS SINTOMAS Y EN LA OBSERVACION DE LA REDUCCION DE LOS SINTOMAS.
ES96929924T 1996-02-13 1996-09-05 Tratamiento de la esclerosis multiple. Expired - Lifetime ES2164916T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/600,913 US5716946A (en) 1996-02-13 1996-02-13 Multiple sclerosis treatment

Publications (1)

Publication Number Publication Date
ES2164916T3 true ES2164916T3 (es) 2002-03-01

Family

ID=24405578

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96929924T Expired - Lifetime ES2164916T3 (es) 1996-02-13 1996-09-05 Tratamiento de la esclerosis multiple.

Country Status (12)

Country Link
US (1) US5716946A (es)
EP (1) EP0880350B1 (es)
JP (1) JP3701687B2 (es)
KR (1) KR100347657B1 (es)
AT (1) ATE209483T1 (es)
AU (1) AU6915396A (es)
CA (1) CA2245661C (es)
DE (1) DE69617469T2 (es)
DK (1) DK0880350T3 (es)
ES (1) ES2164916T3 (es)
PT (1) PT880350E (es)
WO (1) WO1997029740A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
KR20010012770A (ko) 1997-05-22 2001-02-26 세파론, 인코포레이티드 비타민 ｄ 유사체 및 그 뉴런 효과
US5972917A (en) * 1998-05-29 1999-10-26 Bone Care Int Inc 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof
CA2333256A1 (en) 1998-05-29 1999-12-02 Bone Care International, Inc. Method for making hydroxy-25-ene-vitamin d compounds
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6479474B2 (en) * 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
ATE462689T1 (de) * 1999-08-27 2010-04-15 Hiroaki Takayama Vitamin-d-derivate mit substituenten an der 2- alpha-position
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US7012086B1 (en) 2000-06-30 2006-03-14 The Foundation For Innovative Therapies, Inc. Treatment of retrovirus induced derangements with niacin compounds
US20050175585A1 (en) * 2001-06-11 2005-08-11 Transition Therapeutics Inc. Combination therapies using vitamin B12 and interferon for treatment of viral proliferative and inflammatory disesases
EP1401483A1 (en) * 2001-06-11 2004-03-31 Transition Therapeutics Inc. Combination therapies using vitamin b12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
ATE475883T1 (de) * 2001-12-04 2010-08-15 Teva Pharma Verfahren zur messung der wirkstärke von glatirameracetat
NZ534125A (en) * 2002-02-20 2006-11-30 Emisphere Tech Inc A formulation comprising a GLP-1 compound and a delivery agent
PL214283B1 (pl) * 2002-08-08 2013-07-31 Baylor College Medicine Sposób izolacji komórek T, sposób wytwarzania autologicznej szczepionki komórek T, autologiczna szczepionka komórek T, zastosowanie autologicznej szczepionki komórek T
US7566696B2 (en) * 2002-09-05 2009-07-28 Wisconsin Alumni Research Foundation Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
WO2004035086A2 (en) * 2002-10-16 2004-04-29 Hunter Samuel F Method for treatment of demyelinating central nervous system disease using gm-csf
US20050054620A1 (en) * 2003-01-13 2005-03-10 Koeffler H. Phillip Paricalcitol as a chemotherapeutic agent
CA2518079A1 (en) * 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
WO2006032053A2 (en) * 2004-09-14 2006-03-23 Teva Pharmaceutical Industries, Ltd. Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds
WO2006088765A1 (en) * 2005-02-14 2006-08-24 Wisconsin Alumni Research Foundation Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
PL2420833T3 (pl) * 2006-05-05 2016-03-31 Opexa Therapeutics Szczepionka z komórek T
WO2009097614A1 (en) * 2008-02-01 2009-08-06 Wisconsin Alumni Research Foundation Methods of treating multiple sclerosis by administering pulse dose calcitrol
US20140296190A1 (en) * 2013-03-27 2014-10-02 Dsm Ip Assets B.V. Marketing the use of 25-hydroxyvitamin d3 to enhance cognition
CN109071632B (zh) 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
EP3576765A4 (en) 2017-02-06 2020-12-02 Orionis Biosciences, Inc. TARGETED ENGINEERING INTERFERON AND USES OF IT
CN110546160A (zh) 2017-02-06 2019-12-06 奥里尼斯生物科学公司 靶向嵌合蛋白及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4279826A (en) * 1980-09-22 1981-07-21 Wisconsin Alumni Research Foundation 23,25-Dihydroxyvitamin D3
US4307025A (en) * 1981-02-17 1981-12-22 Wisconsin Alumni Research Foundation 1α, 25-dihydroxy-2β-fluorovitamin D3
US4448721A (en) * 1982-09-20 1984-05-15 Wisconsin Alumni Research Foundation Hydroxyvitamin D2 compounds and process for preparing same
US5036061A (en) * 1983-05-09 1991-07-30 Deluca Hector F Process for the preparation of 1 alpha,25-dihydroxylated vitamin D2 and related compounds
US4500460A (en) * 1983-08-18 1985-02-19 Wisconsin Alumni Research Foundation 23,23-Difluoro-25-hydroxy-vitamin D3 and process for preparing same
US4502991A (en) * 1983-08-18 1985-03-05 Wisconsin Alumni Research Foundation 23,23-Difluoro-1α,25-dihydroxy-vitamin D3
US4769181A (en) * 1983-11-07 1988-09-06 Wisconsin Alumni Research Foundation 1,25-dihydroxyvitamin D2 compounds
US4505906A (en) * 1984-01-30 1985-03-19 Wisconsin Alumni Research Foundation Hydroxyvitamin D2 isomers
US4588528A (en) * 1984-05-31 1986-05-13 Wisconsin Alumni Research Foundation 1,24-dihydroxy-Δ22 -vitamin D3 and process for preparing same
US4594192A (en) * 1985-03-20 1986-06-10 Wisconsin Alumni Research Foundation 2α-fluorovitamin D3
US4619920A (en) * 1985-09-16 1986-10-28 Wisconsin Alumni Research Foundation 26,26,26,27,27-pentafluoro-1α-hydroxy-27-methoxyvitamin D3
JPS63104926A (ja) * 1986-10-21 1988-05-10 Teijin Ltd 老年性痴呆症治療又は予防剤
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US4973584A (en) * 1989-03-09 1990-11-27 Deluca Hector F Novel 1α-hydroxyvitamin D2 epimer and derivatives
US5030772A (en) * 1990-02-14 1991-07-09 Deluca Hector F Process for preparing vitamin D2 compounds and the corresponding 1 α-hydroxylated derivatives
US5260290A (en) * 1990-02-14 1993-11-09 Wisconsin Alumni Research Foundation Homologated vitamin D2 compounds and the corresponding 1α-hydroxylated derivatives
JP2845342B2 (ja) * 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
US5260199A (en) * 1991-07-30 1993-11-09 Wisconsin Alumni Research Foundation Method of producing 1,25-dihydroxyvitamin D3 receptor protein
EP0549318B1 (en) * 1991-12-26 1996-10-16 Wisconsin Alumni Research Foundation 26,27-Dimethylene-1 alpha, 25-dihydroxyvitamin D2 and 26,27-dihydroxyvitamin D2 and methods for preparing same
AU666529B2 (en) * 1992-04-24 1996-02-15 Wisconsin Alumni Research Foundation Method of treating osteoporosis with 1 alpha, 24 (R)-dihydroxy-22 (E)-dehydro-vitamin D3
TW272187B (es) * 1992-05-20 1996-03-11 Hoffmann La Roche
US5371249A (en) * 1993-05-11 1994-12-06 Wisconsin Alumni Research Foundation Iodo vitamin D3 compounds and method for preparing same
US5380720A (en) * 1993-05-11 1995-01-10 Wisconsin Alumni Research Foundation Iodo vitamin D3 compounds and method for preparing same
CA2166898C (en) * 1993-07-09 2004-09-07 Roger Bouillon Novel structural analogues of vitamin d
US5373004A (en) * 1993-11-24 1994-12-13 Wisconsin Alumni Research Foundation 26,28-methylene-1α, 25-dihydroxyvitamin D2 compounds
US5471382A (en) * 1994-01-10 1995-11-28 Informed Access Systems, Inc. Medical network management system and process

Also Published As

Publication number Publication date
EP0880350A1 (en) 1998-12-02
AU6915396A (en) 1997-09-02
KR100347657B1 (ko) 2002-11-25
WO1997029740A1 (en) 1997-08-21
JPH11510819A (ja) 1999-09-21
JP3701687B2 (ja) 2005-10-05
ATE209483T1 (de) 2001-12-15
PT880350E (pt) 2002-04-29
US5716946A (en) 1998-02-10
KR19990082492A (ko) 1999-11-25
CA2245661C (en) 2004-02-03
CA2245661A1 (en) 1997-08-21
DK0880350T3 (da) 2002-03-25
EP0880350B1 (en) 2001-11-28
DE69617469D1 (de) 2002-01-10
DE69617469T2 (de) 2002-07-18

Similar Documents

Publication Publication Date Title
ES2164916T3 (es) Tratamiento de la esclerosis multiple.
EP0831832A4 (en) METHODS FOR CONTROLLING INFECTIOUS DISEASES USING DICATIONIC BIS-BENZIMIDAZOLES
DE69325366D1 (de) Verfahren zur hautpflege und mittel
HU9700056D0 (en) New pharmaceutical composition for treating pains
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
FR2739029B1 (fr) Nouvelle application therapeutique des composes antimineralo-corticoides
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
PL340884A1 (en) Application of photolipide obtained from vitis vinifera extracts as antiarteriosclerotic agents
HK1037980A1 (en) Use of selegiline or desmethylselegiline for the manufacture of a medicament for treating wounds, burns or photodamage.
SE9601395D0 (sv) New therapeutic treatment 1
DE69430924D1 (de) Antirestenoses protein
AU4370900A (en) Treatment of systemic lupus erythematosis
EP1056458A4 (en) METHODS FOR TREATING PAIN, INCLUDING CHRONIC AND WOMAN-SPECIFIC PAIN
BR0115215A (pt) Método para o tratamento de inflamações
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
PT859630E (pt) Combinacao de temozolomida e alfa-ifn no tratamento de cancro avancado
NO984198L (no) FremgangsmÕte for behandling av aggresjon
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
MY118982A (en) Method of reducing tissue damage associated with ischemia
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
MX9700626A (es) USO DE AZASPIRANOS EN LA REPARACIaN DE COMPOSICIONES PARA TRATAR INFECCIONES OPORTUNISTAS.
RU94024337A (ru) Антиметастатическое средство
WO1998025594A3 (en) Lamotrigine in the treatment and prophylaxis of migraine
DE69626691D1 (de) Komponente b als wundheilendes mittel
TNSN03022A1 (en) Method for treatment of inflammation

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 880350

Country of ref document: ES